Evidence map›Paper›PMID 27635187›Full record

ArticleOxidative medicine and cellular longevity2016

AMP-Activated Protein Kinase Attenuates High Salt-Induced Activation of Epithelial Sodium Channels (ENaC) in Human Umbilical Vein Endothelial Cells.

Wei-Wan Zheng, Xin-Yuan Li, Hui-Bin Liu, Zi-Rui Wang, Qing-Qing Hu, Yu-Xia Li, Bin-Lin Song, Jie Lou, Qiu-Shi Wang, He-Ping Ma and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Oxidative medicine and cellular longevity, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Effects of Different NaFoods (Basel, Switzerland) · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Wei-Wan ZhengDepartments of Cardiology and Clinical Pharmacy, Harbin Medical University Cancer Hospital, Institute of Metabolic Disease, Heilongjiang Academy of Medical Science, Key Laboratories of Education Ministry for Myocardial Ischemia Mechanism and Treatment, Harbin 150000, China.ORCID 0000-0001-7659-3429
Xin-Yuan LiDepartments of Cardiology and Clinical Pharmacy, Harbin Medical University Cancer Hospital, Institute of Metabolic Disease, Heilongjiang Academy of Medical Science, Key Laboratories of Education Ministry for Myocardial Ischemia Mechanism and Treatment, Harbin 150000, China.
Hui-Bin LiuDepartment of Clinical Pharmacy, Institute of Clinical Pharmacy, The 2nd Affiliated Hospital, Harbin Medical University, Harbin 150086, China.ORCID 0000-0002-9535-3719
Zi-Rui WangDepartments of Cardiology and Clinical Pharmacy, Harbin Medical University Cancer Hospital, Institute of Metabolic Disease, Heilongjiang Academy of Medical Science, Key Laboratories of Education Ministry for Myocardial Ischemia Mechanism and Treatment, Harbin 150000, China.ORCID 0000-0002-3301-3225
Qing-Qing HuDepartments of Cardiology and Clinical Pharmacy, Harbin Medical University Cancer Hospital, Institute of Metabolic Disease, Heilongjiang Academy of Medical Science, Key Laboratories of Education Ministry for Myocardial Ischemia Mechanism and Treatment, Harbin 150000, China.
Yu-Xia LiDepartments of Cardiology and Clinical Pharmacy, Harbin Medical University Cancer Hospital, Institute of Metabolic Disease, Heilongjiang Academy of Medical Science, Key Laboratories of Education Ministry for Myocardial Ischemia Mechanism and Treatment, Harbin 150000, China.ORCID 0000-0001-7313-0170
Bin-Lin SongDepartments of Cardiology and Clinical Pharmacy, Harbin Medical University Cancer Hospital, Institute of Metabolic Disease, Heilongjiang Academy of Medical Science, Key Laboratories of Education Ministry for Myocardial Ischemia Mechanism and Treatment, Harbin 150000, China.ORCID 0000-0003-4455-4825
Jie LouDepartments of Cardiology and Clinical Pharmacy, Harbin Medical University Cancer Hospital, Institute of Metabolic Disease, Heilongjiang Academy of Medical Science, Key Laboratories of Education Ministry for Myocardial Ischemia Mechanism and Treatment, Harbin 150000, China; Department of Clinical Pharmacy, Institute of Clinical Pharmacy, The 2nd Affiliated Hospital, Harbin Medical University, Harbin 150086, China.ORCID 0000-0002-2797-6703
Qiu-Shi WangDepartments of Cardiology and Clinical Pharmacy, Harbin Medical University Cancer Hospital, Institute of Metabolic Disease, Heilongjiang Academy of Medical Science, Key Laboratories of Education Ministry for Myocardial Ischemia Mechanism and Treatment, Harbin 150000, China; Department of Clinical Pharmacy, Institute of Clinical Pharmacy, The 2nd Affiliated Hospital, Harbin Medical University, Harbin 150086, China.ORCID 0000-0002-4447-9565
He-Ping MaDepartment of Physiology, Emory University School of Medicine, Atlanta, GA 150040, USA.
Zhi-Ren ZhangDepartments of Cardiology and Clinical Pharmacy, Harbin Medical University Cancer Hospital, Institute of Metabolic Disease, Heilongjiang Academy of Medical Science, Key Laboratories of Education Ministry for Myocardial Ischemia Mechanism and Treatment, Harbin 150000, China; Department of Clinical Pharmacy, Institute of Clinical Pharmacy, The 2nd Affiliated Hospital, Harbin Medical University, Harbin 150086, China.ORCID 0000-0003-1324-6934
Harbin Medical University · CNEmory University · US

Funding

Role of Ion Channels in Kidney DiseasesR01DK100582 · NIDDK · EMORY UNIVERSITY · PI MA, HE-PING · 2014 to 2017
$1.4M
NIDDK NIH HHS R01 DK100582
6 · The paper itself

Abstract

Recent studies suggest that the epithelial sodium channel (ENaC) is expressed in the endothelial cells. To test whether high salt affects the NO production via regulation of endothelial ENaC, human umbilical vein endothelial cells (HUVECs) were incubated in solutions containing either normal or high sodium (additional 20 mM NaCl). Our data showed that high sodium treatment significantly increased α-, β-, and γ-ENaC expression levels in HUVECs. Using the cell-attached patch-clamp technique, we demonstrated that high sodium treatment significantly increased ENaC open probability (P O ). Moreover, nitric oxide synthase (eNOS) phosphorylation (Ser 1177) levels and NO production were significantly decreased by high sodium in HUVECs; the effects of high sodium on eNOS phosphorylation and NO production were inhibited by a specific ENaC blocker, amiloride. Our results showed that high sodium decreased AMP-activated kinase (AMPK) phosphorylation in endothelial cells. On the other hand, metformin, an AMPK activator, prevented high sodium-induced upregulation of ENaC expression and P O . Moreover, metformin prevented high salt-induced decrease in NO production and eNOS phosphorylation. These results suggest that high sodium stimulates ENaC activation by negatively modulating AMPK activity, thereby leading to reduction in eNOS activity and NO production in endothelial cells.

Indexed as

Action PotentialsAMP-Activated Protein KinasesCell SurvivalEpithelial Sodium ChannelsHumansHuman Umbilical Vein Endothelial CellsMetforminMicroscopy, ConfocalNitric OxideNitric Oxide Synthase Type IIIPatch-Clamp TechniquesPhosphorylationProtein SubunitsSodium ChlorideUp-RegulationAMP-Activated Protein KinasesEpithelial Sodium ChannelsMetforminNitric OxideNitric Oxide Synthase Type IIINOS3 protein, humanProtein SubunitsSodium Chloride

Identifiers

PMID27635187
PMCPMC5011216
OpenAlexW2509303900

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.